CVKD

Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.

Wall Street analysts forecast CVKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cadrenal Therapeutics Inc revenue for the last quarter amounts to -2.73M USD, increased 11.13 % YoY.

Cadrenal Therapeutics Inc. EPS for the last quarter amounts to -2357150.00 USD, decreased % YoY.

Cadrenal Therapeutics Inc (CVKD) has 4 emplpoyees as of December 16 2025.

Today CVKD has the market capitalization of 25.39M USD.